BioCentury
ARTICLE | Clinical News

Quadramet: Phase II data

June 11, 2007 7:00 AM UTC

In an investigator-sponsored Phase II trial in 43 patients, Quadramet plus docetaxel produced median PSA progression-free survival of 7 months. Median survival was about 30 months. The combination was...